Among the variety of tumour surface markers, targeting neuropeptide receptors has been a successful approach for nuclear imaging and therapy of patients suffering from neuroendocrine tumours.[30] Other neuropeptide receptors are on the horizon.[31] Among them, the Gastrin‐Releasing Peptide Receptor (GRPR) and the neurotensin receptor‐1 (NTS1) hold great promise. The gene discussed is NTS; the disease is neuroendocrine neoplasm.